| Title |
Cost of poor adherence to anti-hypertensive therapy in five European countries
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, January 2014
|
| DOI | 10.1007/s10198-013-0554-4 |
| Pubmed ID | |
| Authors |
F. S. Mennini, A. Marcellusi, J. M. Graf von der Schulenburg, A. Gray, P. Levy, P. Sciattella, M. Soro, G. Staffiero, J. Zeidler, A. Maggioni, R. E. Schmieder |
| Abstract |
The financial burden for EU health systems associated with cardiovascular disease (CV) has been estimated to be nearly <euro>110 billion in 2006, corresponding to 10 % of total healthcare expenditure across EU or a mean <euro>223 annual cost per capita. The main purpose of this study is to estimate the costs related to hypertension and the economic impact of increasing adherence to anti-hypertensive therapy in five European countries (Italy, Germany, France, Spain and England). A probabilistic prevalence-based decision tree model was developed to estimate the direct costs of CV related to hypertension (CV defined as: stroke, heart attack, heart failure) in five European countries. Our model considered adherence to hypertension treatment as a main driver of blood pressure (BP) control (BP < 140/90 mmHg). Relative risk of CV, based on controlled or uncontrolled BP group, was estimated from the Framingham Heart Study and national review data. Prevalence and cost data were estimated from national literature reviews. A national payer (NP) perspective for 10 years was considered. Probabilistic sensitivity analysis was performed in order to evaluate uncertainty around the results (given as 95 % confidence intervals). The model estimated a total of 8.6 million (1.4 in Italy, 3.3 in Germany, 1.2 in Spain, 1.8 in France and 0.9 in England) CV events related to hypertension over the 10-year time horizon. Increasing the adherence rate to anti-hypertensive therapy to 70 % (baseline value is different for each country) would lead to 82,235 fewer CV events (24,058 in Italy, 7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England). From the NP perspective, the direct cost associated with hypertension was estimated to be <euro>51.3 billion (8.1 in Italy, 17.1 in Germany, 12.2 in Spain, 8.8 in France and 5.0 in England). Increasing adherence to anti-hypertensive therapy to 70 % would save a total of <euro>332 million (CI 95 %: <euro>319-346 million) from the NPs perspective. This study is the first attempt to estimate the economic impact of non-adherence amongst patients with diagnosed hypertension in Europe, using data from five European countries (Italy, France, Germany, Spain and England). |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 29% |
| Venezuela, Bolivarian Republic of | 1 | 14% |
| United Kingdom | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Peru | 1 | <1% |
| Unknown | 173 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 15% |
| Student > Master | 24 | 14% |
| Student > Ph. D. Student | 19 | 11% |
| Other | 15 | 9% |
| Student > Bachelor | 13 | 7% |
| Other | 37 | 21% |
| Unknown | 42 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 31% |
| Nursing and Health Professions | 16 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
| Economics, Econometrics and Finance | 8 | 5% |
| Psychology | 7 | 4% |
| Other | 28 | 16% |
| Unknown | 54 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2015.
All research outputs
#7,895,727
of 25,371,288 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#528
of 1,303 outputs
Outputs of similar age
#86,922
of 318,765 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#16
of 33 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,303 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,765 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.